Comorbidity effects on shoulder arthroplasty costs analysis of a nationwide private payer insurance data set

Abstract

Shoulder arthroplasty reimbursements are significantly affected by comorbidities at time intervals following the initial surgical day.

Effects of Estimated Glomerular Filtration Rate on 30-Day Mortality and Postoperative Complications After Total Hip Arthroplasty: A Risk Stratification Instrument

“…CKD increases the mean episode of care (day of surgery and up to postoperative day 90) reimbursement of a THA by as much as $1400 and is among the top 5 highest reimbursements at $26,555 [18]. Similar results have been found in TKA and total shoulder arthroplasty [19,20].…”

Hypothyroidism Increases 90-Day Complications and Costs Following Primary Total Knee Arthroplasty

“…This publically and commercially available HIPAA compliant server provides the ability to identify and track patient information based on International Classification of Disease (ICD) and Current Procedural Terminology (CPT) codes. The ICD and Current Procedural Terminology codes utilized in this search have been previously used in the literature [33,34]. Patients with ICD-9 codes for hypothyroidism were identified based on codes 2440 (postsurgical hypothyroidism), 2441 (other/postablative hypothyroidism), 2442 (iodine hypothyroidism), 2443 (iatrogenic hypothyroidism), and 2448 (acquired hypothyroidism not elsewhere classifiable/other specified acquired hypothyroidism).…”

Impact of Perioperative HbA1c on Reimbursements in Diabetes Mellitus Patients Undergoing Total Hip Arthroplasty: A Nationwide Analysis

“…The cost of THA is multifactorial with surgical implants, length of stay, discharge disposition, rehabilitation, and comorbidity all playing a role [15,18]. Complications following THA have been identified as one of the leading cost drivers [19].…”

“…Patients were stratified into 6 groups based on HbA1c starting at 5.5% and increasing by 1% increments to 11.5%; one additional group (11.5%−20%) for extreme cases was analyzed. Reimbursements were used as a marker for cost in accordance with previous studies [3,14,15]. For each HbA1c subgroup, reimbursements were analyzed and compared for the DOS, subsequent 89 days of surgery, and global 90-day costs in accordance with the Comprehensive Care for Joint Replacement 90-day model.…”